{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:14:26Z","timestamp":1794064466058,"version":"4.8.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hopper Belmont Foundation Inspiration Award","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"Duke Office of Physician Scientist Development Technician Support Award","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA257816"],"award-info":[{"award-number":["CA257816"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01399-w","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:26:48Z","timestamp":1775194008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Profiling KRAS mutations in whole blood by error-corrected maximum depth sequencing"],"prefix":"10.1038","volume":"10","author":[{"given":"Ryne C.","family":"Ramaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Strickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Counter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"1399_CR1","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1001\/jamaoncol.2022.4457","volume":"8","author":"MG Krebs","year":"2022","unstructured":"Krebs, M. G. et al. Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol. 8, 1830 (2022).","journal-title":"JAMA Oncol."},{"issue":"Supplement 1","key":"1399_CR2","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2024-207430","volume":"144","author":"ERS Cliff","year":"2024","unstructured":"Cliff, E. R. S., Russler-Germain, D. A. & Kelkar, A. H. Using Circulating Tumor DNA to Spare Patients with DLBCL Unnecessary Treatment and Cost: A Model-Based Analysis. Blood 144(Supplement 1), 3657\u20133657 (2024).","journal-title":"Blood"},{"key":"1399_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221112696","volume":"14","author":"DA Ezeife","year":"2022","unstructured":"Ezeife, D. A. et al. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Ther. Adv. Med Oncol. 14, 17588359221112696. https:\/\/doi.org\/10.1177\/17588359221112696 (2022).","journal-title":"Ther. Adv. Med Oncol."},{"issue":"2","key":"1399_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/oa-24-00084","volume":"1","author":"VA Nguyen Hoang","year":"2025","unstructured":"Nguyen Hoang, V. A. et al. Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors. JCO Oncol. Adv. 1(2), e2400084. https:\/\/doi.org\/10.1200\/oa-24-00084 (2025).","journal-title":"JCO Oncol. Adv."},{"issue":"224","key":"1399_CR5","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med 6(224), 224ra24 (2014).","journal-title":"Sci. Transl. Med"},{"key":"1399_CR6","doi-asserted-by":"publisher","unstructured":"Martin-Alonso, C. et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science. 383(6680). https:\/\/doi.org\/10.1126\/science.adf2341","DOI":"10.1126\/science.adf2341"},{"issue":"1","key":"1399_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/diagnostics11010125","volume":"11","author":"H Zhou","year":"2021","unstructured":"Zhou, H., Tsou, J. H., Leng, Q. & Jiang, F. Sensitive Detection of KRAS Mutations by Clustered Regularly Interspaced Short Palindromic Repeats. Diagnostics. (Basel) 11(1), 125 (2021).","journal-title":"Diagnostics. (Basel)"},{"issue":"10","key":"1399_CR8","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1038\/s41596-019-0210-2","volume":"14","author":"MJ Kellner","year":"2019","unstructured":"Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O. & Zhang, F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat. Protoc. 14(10), 2986\u20133012 (2019).","journal-title":"Nat. Protoc."},{"issue":"14","key":"1399_CR9","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1158\/0008-5472.CAN-11-4037","volume":"72","author":"A Narayan","year":"2012","unstructured":"Narayan, A. et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 72(14), 3492\u20133498 (2012).","journal-title":"Cancer Res"},{"key":"1399_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2024.116839","volume":"267","author":"S Kocabey","year":"2025","unstructured":"Kocabey, S., Cattin, S., Gray, I. & R\u00fcegg, C. Ultrasensitive detection of cancer-associated nucleic acids and mutations by primer exchange reaction-based signal amplification and flow cytometry. Biosens. Bioelectron. 267, 116839. https:\/\/doi.org\/10.1016\/j.bios.2024.116839 (2025).","journal-title":"Biosens. Bioelectron."},{"issue":"58","key":"1399_CR11","doi-asserted-by":"publisher","first-page":"97769","DOI":"10.18632\/oncotarget.22080","volume":"8","author":"I Chen","year":"2017","unstructured":"Chen, I. et al. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget 8(58), 97769\u201397786 (2017).","journal-title":"Oncotarget"},{"issue":"4","key":"1399_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.7150\/jca.49647","volume":"12","author":"JX Yin","year":"2021","unstructured":"Yin, J. X., Hu, W. W., Gu, H. & Fang, J. M. Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer. J. Cancer. 12(4), 1258\u20131269 (2021).","journal-title":"J. Cancer"},{"key":"1399_CR13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3389\/fonc.2019.01295","volume":"9","author":"ZY Wang","year":"2019","unstructured":"Wang, Z. Y. et al. KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients. Front Oncol. 9, 1295 (2019).","journal-title":"Front Oncol."},{"key":"1399_CR14","doi-asserted-by":"crossref","unstructured":"Tran, L. S. et al. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. PLoS ONE. 14(12):e0226193 (2019).","DOI":"10.1371\/journal.pone.0226193"},{"issue":"11","key":"1399_CR15","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.3390\/cells9112514","volume":"9","author":"K Michaelidou","year":"2020","unstructured":"Michaelidou, K. et al. Detection of KRAS G12\/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. Cells. 9(11), 2514 (2020).","journal-title":"Cells"},{"key":"1399_CR16","doi-asserted-by":"crossref","unstructured":"Cho, M. S., Park, C. H., Lee, S. & Park, H. S. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation. PLoS ONE. 15(3):e0230622 (2020).","DOI":"10.1371\/journal.pone.0230622"},{"issue":"4","key":"1399_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1158\/1078-0432.CCR-09-2672","volume":"16","author":"S Wang","year":"2010","unstructured":"Wang, S. et al. Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non\u2013Small Cell Lung Cancer. Clin. Cancer Res 16(4), 1324\u20131330 (2010).","journal-title":"Clin. Cancer Res"},{"issue":"22","key":"1399_CR18","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1039\/C8LC00716K","volume":"18","author":"CDM Campos","year":"2018","unstructured":"Campos, C. D. M. et al. Microfluidic-based solid phase extraction of cell free DNA. Lab Chip 18(22), 3459\u20133470 (2018).","journal-title":"Lab Chip"},{"key":"1399_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2021.08.005","volume":"160","author":"A Kulasinghe","year":"2021","unstructured":"Kulasinghe, A. et al. The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer 160, 73\u201377 (2021).","journal-title":"Lung Cancer"},{"issue":"1","key":"1399_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06710-0","volume":"23","author":"M Nouri","year":"2025","unstructured":"Nouri, M., Sharif, S., Soltani, E., Mozaffari-Jovin, S. & Abbaszadegan, M. R. Performance of KRAS mutation detection in plasma exosomes from patients with early-stage colorectal cancer. J. Transl. Med 23(1), 730 (2025).","journal-title":"J. Transl. Med"},{"issue":"1","key":"1399_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47700-9","volume":"9","author":"Y Kitagawa","year":"2019","unstructured":"Kitagawa, Y. et al. Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment. Sci. Rep. 9(1), 11346. https:\/\/doi.org\/10.1038\/s41598-019-47700-9 (2019).","journal-title":"Sci. Rep."},{"key":"1399_CR22","doi-asserted-by":"crossref","unstructured":"Galbiati, S. et al. A New Microarray Substrate for Ultra-Sensitive Genotyping of KRAS and BRAF Gene Variants in Colorectal Cancer. PLoS ONE. 8(3):e59939 (2013).","DOI":"10.1371\/journal.pone.0059939"},{"issue":"1","key":"1399_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2678-2","volume":"16","author":"JY Han","year":"2016","unstructured":"Han, J. Y., Choi, J. J., Kim, J. Y., Han, Y. L. & Lee, G. K. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. BMC Cancer. 16(1), 627 (2016).","journal-title":"BMC Cancer"},{"issue":"9","key":"1399_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/ijms17091505","volume":"17","author":"LE Lowes","year":"2016","unstructured":"Lowes, L. E. et al. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J. Mol. Sci. 17(9), 1505 (2016).","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"1399_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206361","volume":"10","author":"N Liang","year":"2023","unstructured":"Liang, N. et al. Mature Red Blood Cells Contain Long DNA Fragments and Could Acquire DNA from Lung Cancer Tissue. Adv. Sci. (Weinh.) 10(7), e2206361. https:\/\/doi.org\/10.1002\/advs.202206361 (2023).","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"6761","key":"1399_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp3971","volume":"389","author":"L Murphy","year":"2025","unstructured":"Murphy, L. et al. Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA. Science. 389(6761), eadp3971. https:\/\/doi.org\/10.1126\/science.adp3971 (2025).","journal-title":"Science"},{"issue":"5","key":"1399_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrg.2017.117","volume":"19","author":"JJ Salk","year":"2018","unstructured":"Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19(5), 269\u2013285 (2018).","journal-title":"Nat. Rev. Genet"},{"issue":"6","key":"1399_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrg.2016.49","volume":"17","author":"S Goodwin","year":"2016","unstructured":"Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet 17(6), 333\u2013351 (2016).","journal-title":"Nat. Rev. Genet"},{"issue":"7859","key":"1399_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-021-03477-4","volume":"593","author":"F Abascal","year":"2021","unstructured":"Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593(7859), 405\u2013410 (2021).","journal-title":"Nature"},{"issue":"7609","key":"1399_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nature18313","volume":"534","author":"J Jee","year":"2016","unstructured":"Jee, J. et al. Rates and mechanisms of bacterial mutagenesis from maximum-depth sequencing. Nature 534(7609), 693\u2013696 (2016).","journal-title":"Nature"},{"issue":"1","key":"1399_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/21541248.2022.2083895","volume":"13","author":"S Li","year":"2022","unstructured":"Li, S. & Counter, C. M. An ultra-sensitive method to detect mutations in human RAS templates. Small GTPases. 13(1), 287\u2013295 (2022).","journal-title":"Small GTPases"},{"issue":"1","key":"1399_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15660-8","volume":"11","author":"S Li","year":"2020","unstructured":"Li, S., MacAlpine, D. M. & Counter, C. M. Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nat. Commun. 11(1), 1800 (2020).","journal-title":"Nat. Commun."},{"issue":"10","key":"1399_CR33","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","volume":"3","author":"KM Haigis","year":"2017","unstructured":"Haigis, K. M. KRAS Alleles: The Devil Is in the Detail. Trends Cancer 3(10), 686\u2013697 (2017).","journal-title":"Trends Cancer"},{"issue":"3","key":"1399_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1158\/2643-3230.BCD-20-0094","volume":"2","author":"JE Feusier","year":"2021","unstructured":"Feusier, J. E. et al. Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov. 2(3), 226\u2013237 (2021).","journal-title":"Blood Cancer Discov."},{"issue":"3","key":"1399_CR35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 3(3), 272\u2013286 (2022).","journal-title":"Nat. Cancer"},{"issue":"3","key":"1399_CR36","first-page":"308","volume":"4","author":"W Shaib","year":"2013","unstructured":"Shaib, W., Mahajan, R. & El-Rayes, B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J. Gastrointest. Oncol. 4(3), 308\u2013318 (2013).","journal-title":"J. Gastrointest. Oncol."},{"issue":"3","key":"1399_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.22.01423","volume":"41","author":"CM Parseghian","year":"2023","unstructured":"Parseghian, C. M. et al. Resistance Mechanisms to Anti\u2013Epidermal Growth Factor Receptor Therapy in RAS\/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. JCO 41(3), 460\u2013471 (2023).","journal-title":"JCO"},{"key":"1399_CR38","unstructured":"FDA SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) for Guardant360 CDx. Published online August 7, (2020). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/P200010B.pdf"},{"key":"1399_CR39","unstructured":"Foundation Medicine. Technical Specifications of FoundationOne Liquid CDx Assay. Accessed September 22, (2025). https:\/\/www.foundationmedicine.com\/sites\/default\/files\/media\/documents\/2023-10\/F1LCDx_Technical_Specs_072021-2.pdf"},{"issue":"25","key":"1399_CR40","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"Awad","year":"2021","unstructured":"Awad et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N. Engl. J. Med 384(25), 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"1399_CR41","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard, J. Y. et al. Panitumumab\u2013FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N. Engl. J. Med 369(11), 1023\u20131034 (2013).","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"1399_CR42","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. N. Engl. J. Med 360(14), 1408\u20131417 (2009).","journal-title":"N. Engl. J. Med"},{"issue":"15","key":"1399_CR43","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe, J. et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 329(15), 1271 (2023).","journal-title":"JAMA"},{"key":"1399_CR44","unstructured":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 32(2):185-203.e13 (2017)."},{"issue":"2","key":"1399_CR45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese, A. M. et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat. Med 31(2), 466\u2013477 (2025).","journal-title":"Nat. Med"},{"issue":"20","key":"1399_CR46","doi-asserted-by":"publisher","first-page":"7651","DOI":"10.3390\/ijms21207651","volume":"21","author":"MW Grunvald","year":"2020","unstructured":"Grunvald, M. W., Jacobson, R. A., Kuzel, T. M., Pappas, S. G. & Masood, A. Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. Int J. Mol. Sci. 21(20), 7651 (2020).","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"1399_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100259","volume":"3","author":"Q Gao","year":"2022","unstructured":"Gao, Q. et al. Circulating cell-free DNA for cancer early detection. Innovation 3(4), 100259. https:\/\/doi.org\/10.1016\/j.xinn.2022.100259 (2022).","journal-title":"Innovation"},{"issue":"11","key":"1399_CR48","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones, R. P. et al. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg. 154(11), 1038 (2019).","journal-title":"JAMA Surg."},{"issue":"7","key":"1399_CR49","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","volume":"4","author":"JE Murphy","year":"2018","unstructured":"Murphy, J. E. et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 4(7), 963 (2018).","journal-title":"JAMA Oncol."},{"issue":"6","key":"1399_CR50","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.pan.2024.07.017","volume":"24","author":"M Brunner","year":"2024","unstructured":"Brunner, M. et al. Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma \u2013 A retrospective analysis of 272 patients. Pancreatology 24(6), 930\u2013937 (2024).","journal-title":"Pancreatology"},{"issue":"3","key":"1399_CR51","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.surg.2020.06.042","volume":"169","author":"H Kolbeinsson","year":"2021","unstructured":"Kolbeinsson, H. et al. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery 169(3), 649\u2013654 (2021).","journal-title":"Surgery"},{"issue":"4","key":"1399_CR52","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/JS9.0000000000000296","volume":"109","author":"XP Zhang","year":"2023","unstructured":"Zhang, X. P. et al. Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study. Int J. Surg. 109(4), 785\u2013793 (2023).","journal-title":"Int J. Surg."},{"issue":"1","key":"1399_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12957-016-1078-z","volume":"15","author":"K Nishio","year":"2017","unstructured":"Nishio, K. et al. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J. Surg. Oncol. 15(1), 16 (2017).","journal-title":"World J. Surg. Oncol."},{"issue":"2","key":"1399_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/SLA.0000000000003143","volume":"272","author":"SB Dreyer","year":"2020","unstructured":"Dreyer, S. B. et al. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Ann. Surg. 272(2), 366\u2013376 (2020).","journal-title":"Ann. Surg."},{"key":"1399_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.sopen.2024.07.010","volume":"20","author":"T Murakami","year":"2024","unstructured":"Murakami, T. et al. Predictors of occult metastases in potentially resectable pancreatic ductal adenocarcinoma. Surg. Open Sci. 20, 222\u2013229 (2024).","journal-title":"Surg. Open Sci."},{"issue":"1","key":"1399_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04601-z","volume":"7","author":"B Kulemann","year":"2017","unstructured":"Kulemann, B. et al. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Sci. Rep. 7(1), 4510 (2017).","journal-title":"Sci. Rep."},{"issue":"7","key":"1399_CR57","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med 21(7), 795\u2013801 (2015).","journal-title":"Nat. Med"},{"issue":"12","key":"1399_CR58","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 10(12), 1842\u20131853 (2020).","journal-title":"Cancer Discov."},{"issue":"1","key":"1399_CR59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","volume":"34","author":"ZR Reichert","year":"2023","unstructured":"Reichert, Z. R. et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. 34(1), 111\u2013120 (2023).","journal-title":"Ann. Oncol."},{"issue":"1","key":"1399_CR60","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41392-023-01725-9","volume":"8","author":"Q Zhan","year":"2023","unstructured":"Zhan, Q. et al. New insights into the correlations between circulating tumor cells and target organ metastasis. Sig Transduct. Target Ther. 8(1), 465 (2023).","journal-title":"Sig Transduct. Target Ther."},{"key":"1399_CR61","unstructured":"Pancreas Adenocarcinoma. NCCN Guidelines Version 2.2025. Accessed May 5, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"issue":"2","key":"1399_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.hpb.2016.11.001","volume":"19","author":"VP Groot","year":"2017","unstructured":"Groot, V. P. et al. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB (Oxf.) 19(2), 83\u201392 (2017).","journal-title":"HPB (Oxf.)"},{"key":"1399_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1520733","volume":"15","author":"Z Wu","year":"2025","unstructured":"Wu, Z. et al. Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma. Front Oncol. 15, 1520733. https:\/\/doi.org\/10.3389\/fonc.2025.1520733 (2025).","journal-title":"Front Oncol."},{"issue":"1","key":"1399_CR64","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/clinchem\/hvad194","volume":"70","author":"P van der Leest","year":"2024","unstructured":"van der Leest, P. & Schuuring, E. Critical Factors in the Analytical Work Flow of Circulating Tumor DNA-Based Molecular Profiling. Clin. Chem. 70(1), 220\u2013233 (2024).","journal-title":"Clin. Chem."},{"issue":"15_suppl","key":"1399_CR65","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1200\/JCO.2019.37.15_suppl.1507","volume":"37","author":"M Conces","year":"2019","unstructured":"Conces, M. et al. Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies. JCO 37(15_suppl), 1507\u20131507 (2019).","journal-title":"JCO"},{"issue":"5","key":"1399_CR66","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40291-014-0115-2","volume":"18","author":"G Chen","year":"2014","unstructured":"Chen, G., Mosier, S., Gocke, C. D., Lin, M. T. & Eshleman, J. R. Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol. Diagn. Ther. 18(5), 587\u2013593 (2014).","journal-title":"Mol. Diagn. Ther."},{"issue":"1","key":"1399_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet j. 17(1), 10 (2011).","journal-title":"EMBnet j."},{"key":"1399_CR68","doi-asserted-by":"crossref","unstructured":"Bushnell, B., Rood, J. & Singer, E. BBMerge \u2013 Accurate paired shotgun read merging via overlap. PLoS ONE. 12(10):e0185056 (2017).","DOI":"10.1371\/journal.pone.0185056"},{"issue":"3","key":"1399_CR69","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/biomet\/69.3.553","volume":"69","author":"DP Harrington","year":"1982","unstructured":"Harrington, D. P. & Fleming, T. R. A class of rank test procedures for censored survival data. Biometrika 69(3), 553\u2013566 (1982).","journal-title":"Biometrika"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01399-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:03:05Z","timestamp":1780012985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01399-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01399-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pending Patents: C.M.C. is a co-inventor listed on a pending patent application entitled \u201cMethods for detecting oncogenic Kras mutations.\u201d Application number: US-20240141440-A1. Inventors: Christopher Counter and Siqi Li. Current status: pending. This patent covers use Maximum Depth Sequencing to detect mutations in human KRAS. The other authors do not have a competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}